InflaRx N.V. Employee Directory
Biotechnology ResearchThuringia, Germany51-200 Employees
InflaRx N.V. is a biotechnology company focused on anti-inflammatory therapies that aim to disrupt the C5a pathway in the complement system, a mediator involved in many inflammatory diseases. Its lead candidate vilobelimab is an intravenously delivered monoclonal antibody that binds free C5a and has shown disease-modifying activity and tolerability in several clinical studies; INF904 is in development as an oral C5aR inhibitor. The company is based in Jena, Thuringia, Germany, with additional offices in Munich and a presence in Ann Arbor, Michigan. It is listed on Nasdaq under IFRX and was founded in 2007.